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Sahar H. Koubar1*, Michelle M. Estrella2, Rugmini Warrier3, Richard D. Moore4, Gregory M. Lucas4,
Mohamed G. Atta5 and Derek M. Fine5Abstract
Background: The Literature on rhabdomyolysis in the HIV-positive population is sparse and limited. We aimed to
explore the incidence, patient characteristics, etiologies and outcomes of rhabdomyolysis in a cohort of HIV-positive
patients identified through the Johns Hopkins HIV clinical registry between June 1992 and April 2014.
Methods: A retrospective analysis of 362 HIV-positive patients with non-cardiac CK elevation ≥1000 IU/L was performed.
Both inpatients and outpatients were included. Incidence rate and potential etiologies for rhabdomyolysis were
ascertained. The development of acute kidney injury (AKI, defined as doubling of serum creatinine), need for
dialysis, and death in the setting of rhabdomyolysis were determined. Logistic regression was used to evaluate
the association of peak CK level with the development of AKI.
Results: Three hundred sixty two cases of rhabdomyolysis were identified in a cohort of 7079 patients with a
38,382 person years follow-up time. The incidence rate was nine cases per 1000 person-years (95% CI: 8.5–10.5).
Infection was the most common etiology followed by compression injury and drug/alcohol use. One-third of
cases had multiple potential etiologies. AKI developed in 46% of cases; 20% of which required dialysis. Thirteen
percent died during follow-up. After adjustment, AKI was associated with higher CK (OR 2.05 for each 1-log
increase in CK [95% CI: 1.40–2.99]), infection (OR 5.48 [95% CI 2.65–11.31]) and higher HIV viral load (OR 1.22 per
1-log increase [95% CI: 1.03–1.45]).
Conclusion: Rhabdomyolysis in the HIV-positive population has many possible causes and is frequently multifactorial.
HIV-positive individuals with rhabdomyolysis have a high risk of AKI and mortality.
Keywords: Acute kidney injury, AIDs, Creatinine kinase, HIV, RhabdomyolysisBackground
Rhabdomyolysis is common in the HIV-positive popula-
tion, particularly in those with advanced disease [1]. A
cohort study from Kaiser Permanente reported a 10-fold
higher incidence of rhabdomyolysis among the HIV-
positive compared with HIV-negative individuals (265
events/100,000 py versus 26 events/100,000 py; 95% CI:
8.5–12.0; p < 0.001) [1]. The spectrum of the illness va-
ries from asymptomatic elevation in muscle breakdown
biomarkers to a life-threatening disease causing severe
acute kidney injury (AKI), major electrolyte disturbances
and death in some cases. Rhabdomyolysis is responsible* Correspondence: sk62@aub.edu.lb
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(http://creativecommons.org/publicdomain/zefor 5–25% of all cases of AKI [2] and is associated with
death in up to 10% of these cases [3].
Risk factors unique to this population include HIV it-
self [4, 5], co-infection with HCV [6, 7], medication-
related adverse effects, drug-drug interactions [8], and
alcohol and illicit drug abuse [9]. Despite the notably
higher incidence of rhabdomyolysis among HIV-positive
persons, the literature in this patient population is sparse.
Studies to date have been relatively small and dependent
on diagnostic codes (e.g. ICD-9 codes) [1, 10–16]. To
more comprehensively evaluate the risk factors for
rhabdomyolysis and its impact on clinical outcomes in the
context of HIV infection, we aimed to investigate the inci-
dence, patient characteristics, etiologies and outcomes of
rhabdomyolysis in a large cohort of HIV-positive patientsle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Koubar et al. BMC Nephrology  (2017) 18:242 Page 2 of 8cared for at a tertiary care center in Maryland, USA
between June 1992 and April 2014.
Methods
Study design and population
Our study was a retrospective cohort study of HIV-
positive individuals who presented with rhabdomyolysis
either as outpatients or inpatients at the Johns Hopkins
Hospital. Patients were identified through the review of
the laboratory records of those enrolled in Johns Hopkins
HIV clinical registry between June 1992 and April 2014.
We included individuals aged 18 years or older with a
creatinine kinase (CK) level ≥ 1000 IU/L. This level is >5
times upper normal limit at our laboratory (200 by the
Roche CK reagent. Indianapolis, IN, 2009) [17] and it has
been used to define rhabdomyolysis in prior studies
[18, 19]. This cut-off level of CK provides a wide range
of levels but excludes mild cases of rhabdomyolysis.
Baseline and peak creatinine kinase levels were re-
corded and the latter was used for analysis. Patients
with an elevated CK as a result of myocardial injury
(determined by chart review) were excluded from the
study. The study was approved by the Johns Hopkins
Medicine Institutional Review Board.
Data collection and classification of causes
Data extraction occurred through extensive review of
the inpatient and outpatient electronic medical records
of the eligible patients. Several demographic characteris-
tics were extracted including age, sex, hepatitis C virus
(HCV) and hepatitis B virus (HBV) serostatus, smoking
history, alcohol use, as well as cocaine and heroin use.
The latter three were categorized as current, remote or
none. Remote status refers to >1 month before the oc-
currence of rhabdomyolysis. Several laboratory parame-
ters were abstracted including peak CK level, CD4 cell
count and HIV-1 viral load. If the latter two were not up
to date during the acute episode, the closest values
within 3 months were used. We defined a suppressed
viral load as <400 copies/ml.
Potential etiologies for rhabdomyolysis in each partici-
pant were identified. We divided the causes into 14 ca-
tegories including compression injury, infection, seizure,
alcohol, cocaine, medications, cardiopulmonary arrest,
surgery, hypokalemia, HIV-associated myositis, physical
exertion, ischemic limb, hypothyroidism, unclear and
miscellaneous. Compression injuries encompassed those
from immobilization, compartment syndrome or direct
trauma. Urine toxicology screens during the episode
were reviewed on each patient and cocaine was consi-
dered a contributing etiology if the toxicology screen
was positive for cocaine. Medications were labeled as an
etiology if these medications were considered as such by
the treating clinicians and if CK levels normalized withdiscontinuation of the medication (s). Cardiopulmonary
arrest was considered an etiology when chest compres-
sions or defibrillation were performed during resusci-
tation. Surgery was considered an etiology when CK
elevation occurred exclusively in the context of pro-
longed surgery or surgery on a limb in the absence of
other identifiable factors. Hypokalemia was considered a
contributing etiology if it was reported as an etiology in
the medical records, and the potassium level was
<2.8 meq/L. Electromyography reports were reviewed
when available. The diagnosis of HIV-associated inflam-
matory myopathy [20, 21] was based on reported diag-
nosis, available electromyography or biopsy reports.
Miscellaneous causes included heat stroke, neuroleptic
malignant syndrome, hypophosphatemia, hypomagnes-
aemia, hypocalcemia, hypothermia, Amyotrophic Lateral
Sclerosis, unknown drug overdose, muscle injection,
hyperosmolar hyperglycemic state, muscle spasms, myo-
clonic jerks, leaky muscle in African American, polyarti-
cular gout and sickle cell crisis [22]. The etiology was
labeled as unclear when rhabdomyolysis was not charac-
terized in the medical record and no etiologies were
identified by review of the historical documents, labora-
tory values and follow-up visits. For the eight patients
who had recurrent episodes of rhabdomyolysis, only the
first episode was included in the analysis.
Outcomes
Patients were treated as inpatients or outpatients. The
primary outcomes of interest were development of AKI
and the need for renal replacement therapy (RRT).
Serum creatinine levels at baseline, peak and recovery
(the lowest within 1 month after the episode of rhabdo-
myolysis) were recorded. AKI was defined as per KDIGO
guidelines defining stage two AKI (doubling of baseline
serum creatinine during the episode of rhabdomyolysis).
We also performed a sensitivity analysis defining AKI as
a rise in serum creatinine of 0.3 mg/dl or greater from
baseline, which corresponds to stage I AKI per KDIGO
guidelines [23]. Our secondary outcomes were duration
of hospital stay and mortality.
Statistical analysis
Statistical analysis was performed using Stata version 13
(StataCorp College Station, Texas). We categorized pa-
tients into three groups according to their peak CK level:
1) low (1000–5000 IU/L); 2) intermediate (>5000 and
≤10,000 IU/L); and 3) high (>10,000 IU/L). Comparisons
between the three categories were performed using chi-
square for categorical variables and analysis of variance
for continuous variables. Univariable and multivariable
logistic regression models were constructed to evaluate
the association between peak CK level and AKI. The mul-
tivariable model was adjusted for potential confounders of
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level, and presence or absence of sepsis. Patients with
end-stage renal disease (ESRD) were excluded from the
analysis of AKI (n = 26). Ordered logistic regression was
used to assess the correlation between CD4 count and dif-
ferent CK categories.Results
Incidence of Rhabdomyolysis
The HIV Clinical registry consisted of 7079 patients with
38,382 person-years of follow-up during the study period
of June 1992 to April 2014. The study spanned the pre
and post-HAART era. Of 413 patients aged 18 years and
older identified as having a CK ≥1000 IU/L, 51 were ex-
cluded. Of those excluded, 18 had an elevated CK of car-
diac origin, and 33 had no clinical data besides their
laboratory data. Therefore, 362 patients were included in
this analysis. The overall incidence rate of rhabdomyoly-
sis defined by a CK level ≥ 1000 IU was 943 cases per
100,000 person-years.Patient characteristics
Table 1 displays the sociodemographic and clinical char-
acteristics of the study cohort. Sixty patients experienced
rhabdomyolysis in the pre-HAART era (1992–1995) and
302 in the post-HAART era (1996–2014). There were
281 outpatients and 81 inpatients. In comparison to the
whole HIV registry, the HIV cohort with rhabdomyolysis
had more males (76% versus 67%), more black raceTable 1 Patient characteristics by CK category
Characteristics Overall (N = 362) CK 1000- < 5
Median Age (y) 45.8 (±9.6) 47
Black (%) 88 88
Males (%) 76 77
HCV positive, n (%) 205 (57) 164 (58)
HBV positive, n (%) 40 (11) 30 (11)
Current Smoker, n (%) 240 (66) 187 (66)
Current Alcohol Use, n (%) 92 (25) 70 (25)
Current Cocaine Use, n (%) 135 (37) 96 (34)
Current Heroin Use, n (%) 123 (34) 86 (30)
No. of possible causes of rhabdomyolysis
1(%) 60 62
2(%) 27 25
3(%) 5.5 4
4(%) 0.3 0
Unclear causes (%) 7 8.5
Median Viral Load, copies/ml 20,580 19,371
Median CD4 count, cells/ml 175 192
CK values in IU/L(88% versus 76%), and higher rates of HCV infection
(57% versus 46%) and HBV infection (11% versus 9%).
Etiologies of Rhabdomyolysis
A higher peak CK level was associated with a greater
number of potential etiologies underlying the rhabdo-
myolysis. Two factors were present in 25%, 30% and 40%
of the cases in the low, intermediate and high CK level
categories, respectively. Three factors were present in
4%, 9% and 11% of the cases in the low, intermediate
and high CK level categories, respectively (Table 1).
Table 2 summarizes the frequencies of the contribu-
ting etiologies for rhabdomyolysis. Infection was the
most common etiology encountered (39% of cases). Two
concurrent infections were present in 24% of cases,
while three concurrent infections were present in 3.5%.
Table 2 also shows the difference in etiologies by
viral load (VL). Not surprisingly, those with detectable
viral load were more likely to have an infectious etio-
logy (p 0.004) while those with suppressed viral load
were more likely to have medications underlying the
cause of their rhabdomyolysis (p < 0.001). Table 3 shows
the different medications responsible for rhabdomyolysis
individually or secondary to drug-drug interactions.
Association of CK level with AKI
Overall, AKI developed in 46% of patients (Table 4).
Higher CK levels were associated with AKI; AKI deve-
loped in 42% of patients in the lower CK category, 58%
in the intermediate CK category and 64% in the higher000 (n = 284) CK 5000–10,000 (n = 33) CK >10,000 (n = 45) P-value
43 42 0.39
85 93 0.47
76 67 0.29
21 (64) 20 (44) 0.17
2 (6) 8 (18) 0.24
21 (64) 32 (71) 0.59
9 (27) 13 (29) 0.82
15 (45) 24 (53) 0.19
15 (45) 22 (49) 0.18
0.003
58 47
30 40
9 11
3 0
0 2
12,514 43,571 0.69
95 187 0.04
Table 2 Etiologic factors underlying development of rhabdomyolysis in the total HIV cohort and according to viral loada
Etiology Overall (n = 362) Viral load <400 copies/ml (n = 71) Viral Load ≥400 copies/ml (n = 291) p-value
Infection 141 (39%) 17 (24%) 124 (43%) 0.004
Pneumonia 75 (21%) 7 (10%) 68 (23%)
Bacteremia 26 (7%) 4 (6%) 22 (8%)
Viral Illness 25 (7%) 3 (4%) 22 (8%)
Pyelonephritis 8 2 6
Endocarditis 7 0 7
Fungemia 7 2 5
Acute antiretroviral illness 6 0 6
Abscess 6 1 5
Line Infection 5 1 4
Necrotizing Fasciitis 5 0 5
Sinusitis 5 1 4
Meningitis 4 0 4
Othersb 12 2 10
Trauma/compression 82 (23%) 25% 22% 0.544
Cocaine 76 (21%) 11% 23% 0.025
Seizure 26 (7%) 7% 7% 0.959
Alcohol 24 (6.6%) 6% 7% 0.707
Medications 22 (6%) 17% 4% <0.001
Cardiopulmonary arrest 20 (6%) 6% 6% 0.964
Surgery 16 6% 4% 0.579
Hypokalemia 12 4% 3% 0.633
HIV Associated Myositis 11 1% 3% 0.372
Physical Exertion 8 1% 2% 0.608
Ischemic Limb 8 4% 2% 0.198
Hypothyroidism 2 1% 1% 0.484
Unclear 25 (7%) 13% 6% 0.032
Miscellaneous 25 (7%) 10% 6% 0.470
aTotal percentages greater than 100% because 33% of patients had multiple etiologies
bOthers include appendicitis, cholecystitis, spontaneous bacterial peritonitis, clostridium difficile colitis, osteomyelitis and proctitis
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required RRT.
When evaluated continuously, each 1-log higher CK
level was associated with a 2.05-fold increased odds of
AKI (95% CI: 1.40–2.99). Other factors associated with
AKI included presence of infection (OR = 5.48 [95% CI
2.65–11.31]) and higher HIV viral load (OR 1.22 [95% CI:
1.03–1.45]). This association of CK level with the de-
velopment of AKI remained significant after adjusting
for age, sex, viral load, CD4 cell count, and presence
of infection (Table 5). This association also remained
significant among the subset of patients in the post-
HAART era, but was not significant among patients
in the pre-HAART era.
When we analyzed the data based on the absolute in-
crease in serum creatinine by ≥0.3 mg/dl from baseline,the incidence of AKI increased to 62%. Similar to the pri-
mary analyses, each 1-log higher CK level was associated
with 2.11-fold higher odds of AKI (95% CI: 1.4–3.2).
Association of CD4 count with CK categories
Higher CD4 counts were associated with lower CK
levels. For each one unit increase in CD4 count, the
odds ratio of being in a CK category ≥1000 IU/L is 0.99.
However, this inverse correlation did not reach statistical
significance (p value 0.99; 95% CI 0.99–1.00).
Hospitalization
The median duration of stay for those 81 patients admit-
ted to the hospital was 5 days (IQR 2–13 days); 9 days
(IQR 3–17 days) for those with AKI versus 4 days (IQR
1–8 days) for those without AKI (p < 0.01). The median
Table 5 Adjusted association of various predictors with odds of
acute kidney injury
Odds Ratio 95% CI P value
CK level, per 1-log higher 2.05 1.40–2.99 <0.01
Infection vs. no infection 5.48 2.65–11.31 <0.01
HIV viral load, per 1-log higher 1.22 1.03–1.45 0.01
CD4 count, per 100 cells/ml higher 0.98 0.85–1.13 0.80
Age, per 10 years older 0.71 0.46–1.08 0.11
Black vs. non-black 0.92 0.29–2.90 0.88
Male vs. female 0.50 0.62–2.81 0.46
Table 3 List of drugs suspected as the cause of rhabdomyolysis
in HIV-positive patients
Drug No. of events (22)
Statin (HMG-CoA reductase inhibitor) 12
Monotherapy 8
Fenofibrate interaction 2
Ritonavir interaction (simvastatin) 1
Raltegravir + Atorvastatin 1
Zidovudine 3
Raltegravir 2
Abacavir 1
Mirtazapine 1
Colchicine 1
Rifampicin 1
Testosterone 1
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CK category, 4 days (IQR 2–12 days) for the interme-
diate CK category and 8 days (IQR 4–15) for the higher
CK category. There was a trend towards increased hos-
pital stay with increased blood CK level but it did not
reach statistical significance (OR 1.7; 95% CI 0.8–3.5;
P value 0.17).
Mortality
Overall, death occurred in 13% of patients. Of those who
developed AKI, 39 patients (25%) died compared to 3
patients (1.7%) in those without AKI (P < 0.01). (Table 4).
Discussion
To the best of our knowledge, this study represents the
largest to date evaluating causes and outcomes of
rhabdomyolysis in an HIV-positive population. Our
study showed a relatively high incidence of rhabdo-
myolysis as defined by CK ≥1000 IU/L. Infection, com-
pression injury and drug/alcohol use were the most
common etiologies present in these patients. In contrast
to other studies, multiple concurrent potential etiologies
were frequently identified in this population.
These processes lead to muscle necrosis through direct
sarcolemmic injury or by interfering with the oxidative
or glycolytic energy pathway, ultimately leading to lethalTable 4 Distribution of AKI in the total HIV cohort and according to
Total Cohort CK Categories
N=336a 1000- < 5000 IU/L (n = 261)
AKI 156/336 (46%) 110 (42%)
RRT 31/336 (9%) 22 (8%)
Death 46/362b (13%) 31/284 (11%)
aESRD (n = 26) were excluded from the analysis
bWhole Cohort was used for analysis of mortalityintra-sarcoplasmic calcium overload, ATP depletion and
subsequently muscle cell death. The incidence of AKI
was very high in this patient population at 46%, though
in large part a result of an infection associated with the
rhabdomyolysis.
The incidence of rhabdomyolysis in our HIV population
was 943 per 100,000 person-years. Reported data from
Kaiser Permanente on HIV-positive individuals showed an
incidence rate of 265 per 100,000 person-years [1]. Studies
assessing incidence rates of rhabdomyolysis in the general
population have specified those based on particular etiolo-
gies. The incidence rate of rhabdomyolysis secondary to
lipid-lowering drugs ranged between 2.46 to 4.4 cases/
100,000 person-years with statin monotherapy and up to
37–60 cases/100,000 person-years with statin/fibrate com-
bination [24, 25]. The latter is comparable to the incidence
rate of rhabdomyolysis associated with statins in our
population which is around 55 per 100,000 person years.
The incidence rate was 22.2 cases per 100,000 person-
years in military trainees with exertional rhabdomyolysis
[26]. Therefore, compared to the prior studies, the inci-
dence rate in our population was significantly higher,
suggesting higher risk of rhabdomyolysis in the HIV-
positive population. This is likely related to the higher risk
of infection in this population, higher rates of drug expo-
sures (illicit and non-illicit), and possibly higher risk of
drug-drug interactions. In addition, differences among
studies with regards to incidence could also be due to
differing thresholds used to define rhabdomyolysis.
Similar to other studies of rhabdomyolysis, the majority
of patients were men. This likely reflects their increasedthe CK level category
5000–10,000 IU/L (n = 30) >10,000 IU/L (n = 45) P-value
17 (57%) 29 (65%) 0.011
2 (7%) 7 (16%) 0.52
7/33 (21%) 8/45 (18%) 0.024
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posure to risk factors.
More than one potential contributory factor was
present in 33% of patients. Multiple risk factors resulted
in more severe injury and higher CK levels. This is in
contrast to the study by Melli et al. which did not show
a correlation between increasing number of risk factors
and higher CK levels [27].
Infection was the most frequently encountered etio-
logy among the HIV-positive population, but it was asso-
ciated with milder CK elevations. Seventy-five percent of
patients with infection had a CK level between 1000 and
5000 IU/L. Sepsis as a major cause for rhabdomyolysis
in the HIV-positive population was identified in six out
of a series of seven patients by Joshi and Liu [16] and in
seven out of a series of 20 by Chariot et al. [15]. Pneu-
monia was the most common etiology identified in our
population; consistent with what has been demonstrated
in a study of 52 patients by Blanco et al. [28] who
assessed infectious versus non-infectious causes of
rhabdomyolysis. Respiratory infections constituted 38%
of the infectious etiologies. This could reflect the fact
that pneumonia accounts for most infectious admissions
to the hospital [29], but also raises the question of
whether hypoxia secondary to pneumonia further poten-
tiates muscle cell necrosis. Two or more concomitant
infections – viral, bacterial or fungal - were seen in
27.5% of our patients. This likely speaks to the immuno-
compromised status of this particular set of patients and
their vulnerability to infectious complications.
Compression injury was the second most common
etiology in our population. We attribute this to the
increased prevalence of poly-substance abuse in our
study population, with associated increased risk for
immobilization and consequent pressure on muscle
groups. It might also reflect the socioeconomic back-
ground of this population that puts them at increased
risk for traumatic injury [30, 31].
HIV-associated inflammatory myositis was present in
11 cases (3%). All of these were in the post-HAART era.
Melli et al. described two cases of HIV associated myo-
sitis over a 9-year period [27]. The increased incidence
in our study might imply an increased recognition of
this disease entity or, possibly, poor adherence of our
study cohort with their antiretroviral therapy, since 10 of
11 had viral load >400 copies per ml.
Statins were responsible for >50% of medication-
induced myotoxicity, whereas in other reports, anti-
psychotic medications were the leading etiology of
medication-induced rhabdomyolysis [27], and the cause
of recurrent rhabdomyolysis in 10% of patients [28]. Our
results are likely explained by the increased prevalence
of dyslipidemia and atherosclerotic disease associated
with cART and thus the increased frequency of statinuse. In addition, drug-drug interactions between statins
(those metabolized through the cytochrome P450 3A4
[CYP3A4] enzyme system: simvastatin, lovastatin, and
atorvastatin) and protease inhibitors, particularly the
powerful CYP3A4 inhibitors ritonavir or cobicistat, are
well known [8]. Previous studies have reported myotoxic
medications to be responsible for 11% of cases [27]. The
lower percentage in our study likely reflects dispropor-
tionate rates of infection, drug and alcohol use in this
cohort, and possibly reflects medication non-adherence
in our patient population.
AKI developed in 46% of our patients. Comparison of
the incidence of rhabdomyolysis associated AKI in the
HIV-positive population to the general population is dif-
ficult due to varying definitions of AKI used and diffe-
rent cutoffs for CK level to define rhabdomyolysis; the
reported incidence in the general population ranges
from 13 to 46%, so that rhabdomyolysis-associated AKI
in this particular HIV-positive population is at least at
the higher end of the spectrum.
Higher CK levels were associated with increased inci-
dence of AKI. This is consistent with findings from se-
veral other studies [3, 32]. Not surprisingly, the need for
RRT was also higher in the higher CK groups, though
the difference did not reach statistical significance be-
tween the three different CK categories. This is likely
secondary to the small proportion that needed dialysis in
each group.
The mortality rate was higher in the intermediate and
high CK groups at 21% and 18% respectively, compared
with 11% in the low CK group. We attributed this high
mortality to the increased proportion of patients with in-
fection in those groups (55% and 38% respectively|),
where CK elevations were likely related to the infection
itself. CK elevation with infection reflects muscle ische-
mia from a prolonged hypo-perfusion which also results
in ischemic renal injury, and intracellular acidosis leads
to ATP depletion and increased risk of muscle necrosis.
In addition, mild elevations of CK have been reported in
febrile patients [33].
As was shown previously by Ward et al. [18], the mor-
tality of hospitalized patients with a CK level > 1000 IU
was higher in those who developed AKI versus those
who did not develop AKI. This was true in our popu-
lation as well. In addition, rhabdomyolysis in this HIV
population was associated with a 1.5–4 fold increase in
the rate of death than the general population (13% in
this study compared to 3.4–10% in the general popula-
tion reported in prior literature) [27].
Our study has several limitations. It is a retrospective
study where data collection was based on chart reviews.
Nonetheless, we did not solely rely on reported diagnosis
in discharge summaries. Follow up clinic notes, response
to interventions/treatments, laboratory values, toxicology
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on each patient when available. Also, this is a single urban
center study with a predominantly African American
population and many of those studied had virologically
uncontrolled HIV disease. As noted above the study also
spanned the different treatment eras of HIV care. These
factors limit its generalizability to other cohorts of diffe-
rent races and ethnicities and less severe HIV disease.
On the other hand, this is the largest HIV cohort stu-
died regarding the epidemiology, causes and outcomes
of rhabdomyolysis. Patients were selected based on their
lab results rather than on ICD 9 codes, which may miss
some mild cases of rhabdomyolysis. To our knowledge,
there are 2 other studies that assessed rhabdomyolysis in
the context of HIV infection. In a series of 20 hospita-
lized HIV-positive patients in France [15], rhabdomyoly-
sis was responsible for 10% of cases of biopsy-proven
AKI. In another series of seven patients, three patients
developed AKI, and one of those patients died [15, 16].
Conclusion
Infection appears to be the most common etiology of
rhabdomyolysis (CK > 1000 IU/L) in HIV-positive pa-
tients. One third of cases are potentially multifactorial.
Both increasing CK level and infection are independently
associated with development of AKI in this cohort.
Rhabdomyolysis in HIV appears to be associated with an
increase in mortality compared with the general popula-
tion. This likely reflects a vulnerable population at in-
creased risk of sepsis, where elevated CK might serve as
a marker of poor outcome in those patients.
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